CN116133687A - B细胞恶性肿瘤的治疗 - Google Patents

B细胞恶性肿瘤的治疗 Download PDF

Info

Publication number
CN116133687A
CN116133687A CN202180062994.8A CN202180062994A CN116133687A CN 116133687 A CN116133687 A CN 116133687A CN 202180062994 A CN202180062994 A CN 202180062994A CN 116133687 A CN116133687 A CN 116133687A
Authority
CN
China
Prior art keywords
binding fragment
baffr antibody
use according
combination
baffr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062994.8A
Other languages
English (en)
Chinese (zh)
Inventor
N·哈苏纳
A·乔杜里
S·乔杜里
J·伍
N·A·P·昆达马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN116133687A publication Critical patent/CN116133687A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seeds, Soups, And Other Foods (AREA)
CN202180062994.8A 2020-08-04 2021-08-02 B细胞恶性肿瘤的治疗 Pending CN116133687A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060786P 2020-08-04 2020-08-04
US63/060,786 2020-08-04
US202063114363P 2020-11-16 2020-11-16
US63/114,363 2020-11-16
US202163147507P 2021-02-09 2021-02-09
US63/147,507 2021-02-09
PCT/US2021/044113 WO2022031567A1 (en) 2020-08-04 2021-08-02 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
CN116133687A true CN116133687A (zh) 2023-05-16

Family

ID=77448106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062994.8A Pending CN116133687A (zh) 2020-08-04 2021-08-02 B细胞恶性肿瘤的治疗

Country Status (10)

Country Link
US (1) US20230279132A1 (https=)
EP (1) EP4192869A1 (https=)
JP (1) JP7834711B2 (https=)
KR (1) KR20230042594A (https=)
CN (1) CN116133687A (https=)
AU (1) AU2021320129B2 (https=)
CA (1) CA3190678A1 (https=)
IL (1) IL300086A (https=)
TW (1) TW202221033A (https=)
WO (1) WO2022031567A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP4628094A3 (en) * 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
KR20220093347A (ko) * 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료

Also Published As

Publication number Publication date
AU2021320129A1 (en) 2023-03-16
IL300086A (en) 2023-03-01
WO2022031567A1 (en) 2022-02-10
JP7834711B2 (ja) 2026-03-24
KR20230042594A (ko) 2023-03-28
AU2021320129B2 (en) 2025-12-18
EP4192869A1 (en) 2023-06-14
CA3190678A1 (en) 2022-02-10
JP2023536596A (ja) 2023-08-28
TW202221033A (zh) 2022-06-01
US20230279132A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
KR102776925B1 (ko) Flt3l-fc 융합 단백질 및 사용 방법
AU2019379325B2 (en) Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
CN113613674B (zh) 治疗小细胞肺癌的联用药物组合物
CA2738598C (en) Composition for treating disease
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN114641312A (zh) 抗cd19疗法与来那度胺组合用于治疗白血病或淋巴瘤
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
US12528864B2 (en) Antigen binding proteins
CN114945409A (zh) 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
AU2021320129B2 (en) Treatment of B cell malignancies
KR20230042377A (ko) Cll 치료
WO2026040955A1 (zh) 双特异性抗cd3/cd20多肽复合物的用途
CN118871129A (zh) 抗tim-3抗体与去甲基化药物的药物组合
EA045919B1 (ru) СЛИТЫЕ БЕЛКИ FLT3L-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN120346313A (zh) 治疗肿瘤的药物组合
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
HK40056403A (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
HK40071848B (zh) Flt3l-fc融合蛋白和使用方法
HK40071848A (en) Flt3l-fc fusion proteins and methods of use
HK1172823A (en) Cd40 antibody formulation and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination